Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.38 |
| ▸ | LIPC | P11150 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462791 | 0.98 | ABCB11 (0.52) | ABCB11P2RX7SIGMAR1LIPGLIPC | |
| SCHEMBL6485285 | 0.84 | P2RX7 (0.53) | P2RX7LIPGLIPCMEN1KMT2A | |
| SCHEMBL4116624 | 0.81 | P2RX7 (0.64) | P2RX7LIPGLIPCMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5960230 | 0.81 | P2RX7 (0.64) | P2RX7LIPGLIPCMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5924089 | 0.81 | P2RX7 (0.64) | P2RX7LIPGLIPCMEN1KMT2A | |
| SCHEMBL4129968 | 0.80 | ABCB11 (0.81) | ABCB11P2RX7 | |
| SCHEMBL4129964 | 0.80 | ABCB11 (0.81) | ABCB11P2RX7 | |
| SCHEMBL5333690 | 0.80 | P2RX7 (0.52) | P2RX7LIPGLIPCMEN1KMT2A | |
| SCHEMBL6052984 | 0.78 | ABCB11 (0.64) | ABCB11P2RX7 | |
| SCHEMBL5142841 | 0.76 | NPC1 (0.44) | P2RX7MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013036295-A1 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036303-A2 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036301-A1 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036302-A1 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036294-A1 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036293-A1 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036297-A1 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036296-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036300-A1 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DEDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036299-A1 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130058901-A1 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058977-A1 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058978-A1 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058894-A1 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059009-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058963-A1 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058970-A1 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058976-A1 | ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058902-A1 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130058974-A1 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059009-A1 | COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS | CD74, HLA-C, CD14 | ABCB11 3825/4885P2RX7 2561/4885SIGMAR1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.